PDS Biotechnology Corp 8K

PDS Biotechnology reported Q2 2026 results and announced a strategic shift to concentrate resources on lead program PDS0301 while halting internal investment in PDS0101 and its VERSATILE-003 Phase 3 trial and pursuing partnerships for its further development.

On August 13, 2026, PDS Biotechnology Corporation reported its financial results for the quarter ended June 30, 2026, and provided a business update, highlighting strong positive Phase 2 metastatic colorectal cancer data for its tumor‑targeted IL‑12 immunocytokine PDS0301 and announcing a strategic refocus to prioritize PDS0301 as its lead development program. As part of this refocus, the company will cease further internal investment in PDS0101, including discontinuation of the VERSATILE-003 Phase 3 trial, and will seek strategic partnerships or other externally funded arrangements for any continued development of PDS0101. The company reported a net loss of $9.8 million for the quarter, reduced operating expenses versus the prior year period, a higher net interest expense driven in part by a non‑cash loss on retirement of debt, and a cash balance of $5.6 million as of June 30, 2026, with total stockholders’ equity in a deficit position.

Filing Facts

CIK

1472091

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-032650

Alert Tier

7